All the clinical trials that demonstrate a robust antitumor efficacy with crizotinib in advanced ROS1+NSCLC patients are single‐arm studies,5, 7, 14 including PROFILE1001 and OO‐1201 study. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.